Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates.

MLA

Albarrán, Víctor, et al. “Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates.” International Journal of Molecular Sciences, vol. 23, no. 20, Oct. 2022, p. 12659–N.PAG. EBSCOhost, https://doi.org/10.3390/ijms232012659.

APA

Albarrán, V., Rosero, D. I., Chamorro, J., Pozas, J., San Román, M., Barrill, A. M., Alía, V., Sotoca, P., Guerrero, P., Calvo, J. C., Orejana, I., Pérez de Aguado, P., & Gajate, P. (2022). Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates. International Journal of Molecular Sciences, 23(20), 12659–N.PAG. https://doi.org/10.3390/ijms232012659

Chicago

Albarrán, Víctor, Diana Isabel Rosero, Jesús Chamorro, Javier Pozas, María San Román, Ana María Barrill, Víctor Alía, et al. 2022. “Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates.” International Journal of Molecular Sciences 23 (20): 12659–N.PAG. doi:10.3390/ijms232012659.